Alexander Loretani is an entrepreneur, scientist, co-founder, and CEO. His work at Geltor focuses on developing food products that better human health. According to sources, Lorestani's interest in food began when he was an MD student at Rutgers University and a Ph.D. student at Princeton.
Lorestani did his undergraduate studies at Boston College.
Rutgers is where Lorestani developed his interest in food products while studying antibiotic resistance during medical school. He graduated from Rutgers with his Medical Doctorate.
Lorestani went on to pursue and obtain a Ph.D. in molecular biology at Princeton. His interest in antibiotic resistance with correlation to food continued.
Geltor is a cellular agricultural company developing sustainable advanced proteins for human health. The proteins are animal and GMO-free, scalable, and ethically sourced. Currently, Geltor is partnered with companies in various industries, including beauty, nutraceuticals, and food/beverage.
5 Minutes With... Alexander Lorestani from Geltor. - Bio Market Insights
August 2, 2019
A DOC2 protein identified by mutational profiling is essential for apicomplexan parasite exocytosis
Andrew Farrell, Sivasakthivel Thirugnanam, Alexander Lorestani, Jeffrey D Dvorin, Keith P Eidell, David JP Ferguson, Brooke R Anderson-White, Manoj T Duraisingh, Gabor T Marth, Marc-Jan Gubbels
January 12, 2012
A family of intermediate filament-like proteins is sequentially assembled into the cytoskeleton of Toxoplasma gondii
Brooke R. Anderson-White, F. Douglas Ivey, Katherine Cheng, Tomasz Szatanek, Alexander Lorestani, Con J. Beckers, David J. P. Ferguson, Nivedita Sahoo, Marc-Jan Gubbels
December 20, 2010
A MORN1‐associated HAD phosphatase in the basal complex is essential for Toxoplasma gondii daughter budding
Klemens Engelberg, F Douglas Ivey, Angela Lin, Maya Kono, Alexander Lorestani, Dave Faugno‐Fusci, Tim‐Wolf Gilberger, Michael White, Marc‐Jan Gubbels
August 1, 2016
A Toxoplasma MORN1 Null Mutant Undergoes Repeated Divisions but Is Defective in Basal Assembly, Apicoplast Division and Cytokinesis
Alexander Lorestani, Lilach Sheiner, Kevin Yang, Seth D. Robertson, Nivedita Sahoo, Carrie F. Brooks, David J. P. Ferguson, Boris Striepen, Marc-Jan Gubbels
August 19, 2010
Geltor CEO Alex Lorestani's take on a future shaped by biodesigned products - SynBioBeta
July 2, 2019
Large-scale filament formation inhibits the activity of CTP synthetase
Rachael M Barry, Anne-Florence Bitbol, Alexander Lorestani, Emeric J Charles, Chris H Habrian, Jesse M Hansen, Hsin-Jung Li, Enoch P Baldwin, Ned S Wingreen, Justin M Kollman, Zemer Gitai
July 16, 2014
Microfluidic-based transcriptomics reveal force-independent bacterial rheosensing
Joseph E Sanfilippo, Alexander Lorestani, Matthias D Koch, Benjamin P Bratton, Albert Siryaporn, Howard A Stone, Zemer Gitai
Targeted proteomic dissection ofToxoplasmacytoskeleton sub-compartments using MORN1
Alexander Lorestani, F. Douglas Ivey, Sivasakthivel Thirugnanam, Michele A. Busby, Gabor T. Marth, Iain M. Cheeseman, Marc-Jan Gubbels
October 11, 2012
Documentaries, videos and podcasts
San Francisco, California
Bioengineered advanced proteins